BioSpace News Archive

Gritstone bio, Inc., a clinical-stage biotechnology company working to develop the world’s most potent vaccines, presented updated Phase 1 data from its CORAL-CEPI study, a Coalition for Epidemic Preparedness Innovations -funded study that is evaluating Gritstone’s self-amplifying mRNA vaccine against COVID-19 in HIV-negative and people living with HIV participants.

ONO Pharmaceutical, Co., Ltd., and Deciphera Pharmaceuticals, Inc. announced that on April 29, 2024, ONO and Deciphera entered into a definitive merger agreement under which ONO will acquire all outstanding shares of Deciphera common stock for US $ 25.60 per share in cash through a tender offer followed by a merger of a wholly owned subsidiary of ONO with and into Deciphera with Deciphera surviving as a wholly owned subsidiary of ONO.

DURECT Corporation announced acceptance of a late-breaking oral presentation at the European Association for the Study of the Liver Congress 2024 to take place June 5-8, 2024 in Milan, Italy.

Mission Bio, a leader in single-cell multi-omics solutions for precision medicine, announced a new publication led by Hervé Avet-Loiseau, MD, PhD, revealing new insights into disease progression of multiple myeloma.

PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company announced an expansion of its peptide discovery collaboration with Swiss-based Novartis Pharma AG.

Enlaza Therapeutics, the first covalent biologic platform company, announced a $100 million Series A financing.

Corning Incorporated announced its first-quarter 2024 results and provided its outlook for second-quarter 2024.

Incyte reports 2024 first quarter financial results, and provides a status update on the Company’s clinical development portfolio.

XOMA Corporation announced it has acquired an economic interest in three women’s health assets - XACIATO™ vaginal gel 2%, Ovaprene®, and Sildenafil Cream, 3.6% - from Daré Bioscience, Inc., for an upfront payment of $22 million.

InflaRx N.V. announced that it will report its first quarter 2024 financial and operating results on May 8, 2024, before the market opens.